04.08.15
Minneapolis, Minn.-based medical device firm Urologix Inc. has hired Scott M. Madson as its chief financial officer, effective April 1.
Madson has more than 30 years of public and private company financial leadership experience, having most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Previously, he was vice president, controller and chief accounting officer for Universal Hospital Services Inc. (UHS), one of the nation’s largest providers of mobile medical equipment and healthcare technology management services.
Madson will report to company CEO Greg Fluet.
“We are excited to welcome Scott to the management team at Urologix,” said Fluet. “In addition to his broad range of skills and experience, his background in mobile healthcare solutions complements both our operations and long-term growth objectives. We are confident that Scott’s financial leadership will provide a positive impact on Urologix’s ability to execute our plan with operating and financial efficiency.”
During his service to Universal Hospital Services, Madson was responsible for supervising accounting staff and had responsibilities in the areas of accounting, external and internal reporting, fixed asset management, and tax matters. He also was involved in mergers and acquisitions, financings and strategic initiatives. Prior to UHS, Madson held finance positions in companies including Nextel Partners and RBC Wealth Management. He began his career in public accounting at Deloitte in Minneapolis, Minn. Madson is a certified public accountant (inactive) and received a bachelor’s degree in business with a major in accounting from the University of Minnesota.
Urologix makes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH). The company’s Cooled Thermo Therapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate, destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms.
Prostiva is a registered trademark of Medtronic plc, and is used under license.
Madson has more than 30 years of public and private company financial leadership experience, having most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Previously, he was vice president, controller and chief accounting officer for Universal Hospital Services Inc. (UHS), one of the nation’s largest providers of mobile medical equipment and healthcare technology management services.
Madson will report to company CEO Greg Fluet.
“We are excited to welcome Scott to the management team at Urologix,” said Fluet. “In addition to his broad range of skills and experience, his background in mobile healthcare solutions complements both our operations and long-term growth objectives. We are confident that Scott’s financial leadership will provide a positive impact on Urologix’s ability to execute our plan with operating and financial efficiency.”
During his service to Universal Hospital Services, Madson was responsible for supervising accounting staff and had responsibilities in the areas of accounting, external and internal reporting, fixed asset management, and tax matters. He also was involved in mergers and acquisitions, financings and strategic initiatives. Prior to UHS, Madson held finance positions in companies including Nextel Partners and RBC Wealth Management. He began his career in public accounting at Deloitte in Minneapolis, Minn. Madson is a certified public accountant (inactive) and received a bachelor’s degree in business with a major in accounting from the University of Minnesota.
Urologix makes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH). The company’s Cooled Thermo Therapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate, destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms.
Prostiva is a registered trademark of Medtronic plc, and is used under license.